Psilera Bioscience News Today

In-depth state and local coverage, plus national and international perspectives. Everyday Ethics discussion leads off the show.

Depression and anxiety seem to be a prevailing mood among the masses, and the clinical diagnosis and treatment of such mental illnesses still leave much to be desired. Adverse side effects from prescription medication and a continued sense of distress have given way to new thought processes and ideas on how mental illness could be treated in the future.This week on MidPoint, chemist and researcher Dr. Chris Witkowski of Psilera Bioscience discusses their development of therapeutic and medicinal ...

The company issued approximately 4.3 million shares to private buyers at a cost of $0.57 per share. Psilera has developed a patent-pending DMT transdermal patch to be assessed in a Phase 1b clinical trial with an investigational new drug (IND) filing with the FDA before the end of the year. Earlier this year, Psilera received DEA approval to research DMT, psilocybin and psilocin. Innovative delivery methods combined with DMT’s short duration of action could lead to a revolutionary new li...

Psilera Expands Team to Include World-Class Researchers and Industry Leaders to Bolster Clinical Psychedelic Pipeline Share Article TAMPA, Fla. (PRWEB) May 11, 2021 Psilera Bioscience (“Psilera”), a Florida-based biotechnology company specializing in the clinical development of psychedelics and analogues is pleased to announce the latest additions to its roster of talent. All bring unique insight to strengthen company leadershi...

Psilera Bioscience Obtains DEA Approval to Conduct Cutting Edge Psychedelics Research Share Article The Drug Enforcement Administration green lights Psilera’s mission to study new DMT and psilocybin treatments for central nervous system disorders We are focused on novel delivery mechanisms to harness neurological benefits while making these treatments more accessible to patients in need. TAMPA, Fla. (PRWEB) February 25, 2021 Psil...

Psilera Bioscience Launches State-of-the-Art Computational Research of Psychedelic-Inspired Compound Library Share Article Psilera is assessing serotonin receptor activation of psychedelic drugs and novel analogues to accelerate and further validate its drug pipeline Serotonin receptor 5-HT2A (purple) crystal structure with example compound (blue ball and stick structure). This translational research is one of many ways that we are raising the bar for the development of psychedelic-based medici...